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Abstract: Autosomal dominant polycystic liver disease results from
mutations in PRKCSH or SEC63. The respective gene products, gluco-
sidase IIb and SEC63p, function in protein translocation and quality
control pathways in the endoplasmic reticulum. Here we show that
glucosidase IIb and Sec63p are required in mice for adequate expres-
sion of a functional complex of the polycystic kidney disease gene
products, polycystin-1 and polycystin-2. We ﬁnd that polycystin-1
is the rate-limiting component of this complex and that there is a
dose–response relationship between cystic dilation and levels of
functional polycystin-1 following mutation of Prkcsh or Sec63.
Reduced expression of polycystin-1 also serves to sensitize the kidney
to cyst formation resulting from mutations in Pkhd1, the recessive
polycystic kidney disease gene. Finally, we show that proteasome
inhibition increases steady-state levels of polycystin-1 in cells lacking
glucosidase IIb and that treatment with a proteasome inhibitor
reduces cystic disease in orthologous gene models of human autoso-
mal dominant polycystic liver.
 2011 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Journal of Hepatology 20
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ukaachen.de (R. Weiskirchen).The cilium, an antenna-like organelle on the surface of most
cells, currently arises much interest and an emerging number
of diseases with a wide phenotypic spectrum have been shown
to be related to ciliary dysfunction, collectively termed ‘‘ciliopa-
thies’’ (Fig. 1A) [1]. Literally all organs can be affected, however,
it is becoming increasingly evident that most ciliopathies have
a cystogenic, especially renal cystogenic component making kid-
ney cyst formation a hallmark feature of ciliopathies. Cystic and
polycystic kidney diseases (PKD) are clinically and genetically
heterogeneous. Autosomal dominant polycystic kidney disease
(ADPKD) is one of the most common Mendelian genetic disorders
with a prevalence of 1:500–1:1000 and 10–15 million affected
individuals worldwide [2]. Most ADPKD patients carry a germline
mutation in the PKD1 gene encoding polycystin-1, the remaining
20% of patients a mutation in PKD2 encoding polycystin-2. While
usually an adult-onset disease, a minor subset of ADPKD patients
show an early and severe manifestation that is clinically indistin-
guishable from patients with ‘‘infantile’’ autosomal recessive
polycystic kidney disease (ARPKD) and mutations in the Polycys-
tic Kidney and Hepatic Disease 1 (PKHD1) gene. As a potential
explanation for this clinical overlap, we could recently show that
some severely affected patients carry multiple PKD alleles in trans
and/or de novo in addition to the familial germline mutation, sug-
gesting a dosage effect and complex network for PKD [3].
While the kidneys are usually the main organ involved,
ADPKD and ARPKD display profound extrarenal disease burden
especially in the liver (Fig. 1B). About 75% of ADPKD patients dis-
play liver cysts in their sixties. Polycystic liver disease (ADPLD)
can also occur isolated as a distinct autosomal dominant trait
and a mutation in either the non-catalytic b subunit of glucosi-
dase II, also termed Protein Kinase C Substrate, Heavy Chain
(PRKCSH), or the SEC63 gene encoding a protein involved in
post-translational translocation of proteins into the endoplasmic
reticulum (ER). Liver cysts in ADPLD are thought to arise from
disconnected intralobular bile ductules and ductal plate malfor-
mation during embryogenesis [4]. Usually, ADPLD is a benign dis-
order with preserved organ function, characterized by the
formation and progressive enlargement of multiple cysts scat-
tered throughout the liver parenchyma which may lead to gross
liver enlargement and displacement of other abdominal organs.
Rare complications are bleeding or cyst infection. In clinical prac-
tice, it can be challenging to decide with certainty if a patient has
ADPKD or ADPLD, particularly because some ADPLD patients also12 vol. 56 j 1201–1203
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harbor some kidney cysts. Morphologically, cysts in ADPLD are
indistinguishable from those found in ADPKD. While factually
all proteins disturbed in PKD and other ciliopathies have their
main site of action in primary cilia and related organelles, it
has always been puzzling that the two proteins altered in ADPLD
are non-ciliary with roles in protein translocation, folding and
quality control in the ER, the largest controllable intracellular
Ca2+ store in non-excitable cells. Thus, Ca2+ homeostasis, known
to be of relevance in PKD, is largely regulated by the ER. More-
over, the largest pool of polycystin-2, a member of the transientFPC
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1202 Journal of Hepatology 2012receptor potential (TRP) superfamily of Ca2+-permeable cation
channels, is located in the ER.
The recent study by Fedeles and colleagues [5] nicely demon-
strates that ciliopathies and related disorders not only depend on
proper cilia function and structure, but that also other mecha-
nisms such as trafﬁcking and quality control processes within
the cell play a major role (Fig. 1C). Almost every third protein
encoded by the human genome passes through the translocation
and quality control machinery in the ER. This especially holds
true for secretory proteins and transmembrane proteins, as all
PKD genes are. Thus, the authors hypothesized an interrelation-
ship through which PKD and PLD overlap not only clinically,
but also genetically and functionally. To conﬁrm this, they per-
formed a series of different experiments using both genetically
engineered mouse models and biochemical analyses.
In mice, they showed that tissue-selective loss of the ADPLD
genes/proteins is sufﬁcient to cause cyst formation in both the
liver and kidney. While the ﬁrst is not unexpected, the latter was
surprising and prompted the authors to hypothesize that renal
cyst formation and progression was related to a reduced dosage
of the ADPKD proteins. Indeed, the homozygous Prkcsh and
Sec63 ﬂoxed Ksp-Cre PKD mice compounded with either a
Pkd1+/ or Pkd2+/ background displayed amore severe phenotype
especially with Pkd1. In contrast to published data with overex-
pression of either polycystin-1 or polycystin-2 in mice leading to
PKD [6,7], Fedeles and colleagues found that expressing more
polycystin-1 abrogated the kidney and liver cystic phenotype in
both tissue-selective ADPLD mouse models, whereas this was
not the case for Pkd2. In this experimental setup, some functional
polycystin-2 was necessary for the rescuing function of Pkd1 in
line with the ﬁnding that both proteins form an active polycy-
stin-complex [1,2]. Based on these data and known interrelation-
ships, impaired biogenesis following loss of either ADPLD gene
product could be expected for both polycystins and other integral
membrane proteins. However, only polycystin-1 trafﬁcking to
cilia, and not polycystin-2, was considerably reduced. Overall, cyst
formation in both ADPLD mouse models was dynamically deter-
mined by the levels of functional polycystin-1 dosage. Therefore,
the authors speculated that a potential novel therapeutic target
for ADPLD might be proteasome inhibition with stabilization of
polycystin-1, and indeed this hypothesis was substantiated in a
ﬁnal experiment in which it was demonstrated that the protea-
some inhibitors MG132 and carﬁlzomib increased polycystin-1
levels resulting in reduced cystic disease in ADPLD mice.Fig. 1. Polycystic kidney and liver disease is controlled by a network of
different genes/proteins and depend on proper cilium function and structure,
but also trafﬁcking and quality control processes. In the schematic diagram,
the organization of a primary cilium and associated processes are depicted.
Polycystic liver disease can occur as a distinct autosomal dominant trait with
cysts usually exclusively found in the liver (ADPLD) or as part of autosomal
dominant (ADPKD) or recessive (ARPKD) polycystic kidney disease, in the latter
mostly in form of ductal plate malformation with hyperplastic biliary ducts and
congenital hepatic ﬁbrosis. Most cystoproteins, among them the ADPKD proteins
polycystin-1 (PC1) and polycystin-2 (PC2) and the ARPKD protein ﬁbrocystin/
polyductin (FPC), have their main site of action in primary cilia and related
organelles. FPC is in the same complex as PC2 and crucial for its channel function.
PC1 and PC2 directly interact and form a heteromeric complex that stabilizes FPC
thereby modifying severity of cyst formation. In contrast, GIIb and SEC63p, the
two proteins altered in ADPLD, are non-ciliary and control protein translocation,
folding and quality control pathways in the endoplasmic reticulum (ER). All PKD
genes are transmembrane proteins passing through the translocation and quality
control machinery in the ER. Thus, PKD and PLD overlap not only clinically, but
also genetically and functionally.
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In a further series of experiments, the interrelationship
between the above genes and the ARPKD gene Pkhd1 was exam-
ined for good reasons: ﬁrst, the ARPKD protein ﬁbrocystin/poly-
ductin is another ER-passing transmembrane protein, and
second, there is increasing evidence for genetic interaction
between ADPKD and ARPKD. Thus, aggravation of the phenotype
when crossing Sec63ﬂox/ﬂox; Ksp-Cre and Pkhd1del4/del4 mice was not
surprising; however, the phenotype was not as severe as when
crossed with Pkd1+/ mice. In line with our results in PKD
patients [3] and other published data [8], reduction of the Pkd1
dosage led to a more severe phenotype in Pkhd1 mice. Intrigu-
ingly and in contrast to other studies [3,9] the reduced dosage
of polycystin-2 had no effect on the severity of ARPKD.
The present study is crucial for the understanding of polycys-
tic liver and kidney disease and deserves increased attention in
genetic counseling and the management of affected families. Elu-
cidation of the molecular mechanisms that explain variable dis-
ease expression is one of the major issues in genetics. We have
learned from many different individuals suffering from PKD
and/or PLD that there is extensive clinical variability even in
the same family. One family member might be profoundly
affected, whereas another one only shows mild clinical features.
Classical ‘‘Mendelian’’ inheritance patterns are insufﬁcient to
explain these phenomena and understanding effects of individual
mutations in the context of any remaining genomic variation rep-
resents a major challenge for disease interpretation [1,10].
The study by Fedeles and colleagues with identiﬁcation of a
dosage-sensitive network for polycystic liver and kidney disease
may describe a general principle for the modiﬁcation of disease
expression and could have model character for a variety of other
disorders. In this concept, additional hits/mutations (‘‘second-site
modiﬁers’’) exert an aggravating effect and contribute to earlier
and more severe disease expression. On a cellular level, a reces-
sive two-hit disease model has been proposed for ADPKD and
ADPLD [11,12]. According to Knudson’s two-hit model of tumor-
igenesis, second-hit mutation and resulting loss of heterozygosity
(LOH) has been proposed as the mechanism underlying cyst for-
mation. However, there is increasing evidence that this repre-
sents a simpliﬁed model and a germline mutation to one allele
and a somatic mutation to the other one cannot fully explain
cystogenesis. The probably most convincing piece of evidence
for this is that in individuals with germline defects on both
parental alleles by far not every renal tubular cell or nephron
gives rise to a cyst as to be expected in the two-hit scenario
[13]. Therefore, in line with a more complex model, the second-
hit mutation to the other disease allele may act as a modifying
factor that boosts the risk of cyst development and/or drives cyst
progression rather than initiates cyst events.
It can be hypothesized that in addition to the compound geno-
types and mutational data recently described, some of the
patients with liver and kidney cysts carry mutations in more than
one gene of the discussed network, consistent with the ﬁndings
by Fedeles et al. Therefore, multiple genes may have to be consid-
ered to be disease-relevant in a patient why it is reasonable to
analyse all those genes in parallel instead of sequentially. Mean-
while, this is technically easily possible and genetic diagnostics
can be done in a time- and cost-effective manner with new
sequencing technologies (Next-generation sequencing/NGS). For
diagnostic purposes, a targeted approach with NGS-panels and
parallel analysis of a bunch of different disease genes is currentlyJournal of Hepatology 2012to be preferred over exome sequencing and all its unsolved ques-
tions such as ethical concerns in particular when utilized in chil-
dren. However, given the dynamic development in this ﬁeld of
medicine this may well change soon and exome or even genome
sequencing may get to the clinic. Improved knowledge of the
mutational load of an individual patient can be expected to be
the ﬁrst step on the way to a patient’s individual risk score and
deserve increased attention also with respect to future therapeu-
tic approaches and study designs.Conﬂict of interest
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